Introduction
============

Bladder cancer is the ninth most common malignancy in the world, and the fourth most common cancer in the United States^\[[@R1]\]^. Men are more than four times more likely to get bladder cancer than women. Bladder cancer has a multifactorial etiology. It has been proposed that the development of bladder cancer is a result of environmental factors such as smoking, occupational exposure to carcinogens, obesity, physical inactivity^\[[@R2]--[@R4]\]^, genetic variants and the interaction of genes with the external factors^\[[@R5]--[@R8]\]^.

MicroRNAs (miRNAs) are a class of small single-stranded noncoding RNA molecules that play key roles in a variety of cellular processes by targeting mRNAs for cleavage or translational repression^\[[@R9]--[@R10]\]^. The data provides strong evidence that dysregulation of miRNAs expression affects the tumorigenesis by acting as oncogenes or tumor suppressors^\[[@R11]--[@R15]\]^. Single-nucleotide polymorphisms (SNPs) in miRNAs can affect cancer susceptibility by disturbing miRNAs biosynthesis and expression, altering mature miRNAs, or by combining with target genes^\[[@R16]--[@R19]\]^.

The miR-34 family members comprises miR-34a, miR-34b, and miR-34c that are encoded by two different primary miRNAs. The miR-34a is encoded by its own transcript, while the miR-34b and miR-34c are encoded by a shared primary transcript (pri-miR-34b/c)^\[[@R20]\]^. A potentially functional rs4938723 variant (T to C substitution), located in the promoter region of pri-miR-34b/c, may affect miR-34b/c expression via genetic and epigenetic mechanisms and in turn influence the individual susceptibility to cancer^\[[@R21]--[@R23]\]^. Though the association between miR-34b/c rs4938723 polymorphism and the risk of developing several cancers were reported in various case-control studies^\[[@R20],[@R23]--[@R34]\]^, but to the best of our knowledge, there is no report concerning the impact of miR-34b/c rs4938723 variant on the risk of bladder cancer. Accordingly, this case-control study was aimed to evaluate the possible association between pri-miR-34b/c rs4938723 polymorphism and susceptibility to bladder cancer in a sample from the Iranian population.

Subjects and methods
====================

Patients
--------

A total of 136 patients with histopathologically confirmed papillary urothelial cancers of the bladder and 144 healthy controls were enrolled in this case-control study. The study design and recruitment procedures were described previously^\[[@R35]\]^. All participants were from the Department of Urology, Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. The local ethics committee of Zahedan University of Medical sciences approved the project and informed us that written consent was obtained from all of the study participants. The genomic DNA was extracted from peripheral blood cells using the salting-out method^\[[@R36]\]^.

Genotyping
----------

Genotyping of the Pri-miR-34b/c rs4938723 polymorphism was done by a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique as explained previously^\[[@R37]\]^. Briefly, the forward and reverse primers to amplify the Pri-miR-34b/c gene sequences containing the rs4938723 polymorphisms were 5′-CCTCTGGGAACCTTCTTTGACCTGT-3′ and 5′-CCTGGGCCTTCTAGTCAA-ATAGTGA-3′, respectively. PCR amplification was done using Prime Taq Premix (Genet Bio, Korea) by the following amplification procedure: denaturation at 95 °C for 5 minutes, followed by 30 cycles of 95 °C for 30 seconds, 57 °C for 30 seconds, 72 °C for 30 seconds, with a final extension of 10 minutes at 72 °C. Ten microliters of the PCR products of 212 bp fragments were digested by NmuCI restriction enzyme (Fermentas) and separated by 2.5% agarose gel electrophoresis. The T allele was undigested (212 bp fragment), but the C allele digested and produced two fragments of 186 and 26 bp **( *Fig. 1*).**

![**Genotypes of pri-miR-34b/c rs4938723.** M: DNA marker; lanes 1, 2: CC genotype; lanes 3, 4: TT genotype. lane 5, 6: TC genotype.](jbr-33-1-24-fig1){#F000201}

Statistical analysis
--------------------

Statistical analysis was carried out using statistical package SPSS 22 software. The categorical and continuous data were analyzed using χ^2^ and *t*-test, respectively. Odds ratio (OR) and 95% confidence interval (CI) was computed by unconditional logistic regression analysis to determine the association between the variant and the bladder cancer. The statistical level of significance was set as the *P*\<0.05 level.

Results
=======

The miR-34b/c rs4938723 *t*\>C polymorphism was successfully genotyped for 136 bladder cancer patients (117 males, 19 females) with an average age of (63.8±12.3) years and 144 controls (134 males, 10 females) with mean age of (64.3±10.2) years. No significant difference was found between the groups regarding age ( *P* = 0.701) and sex ( *P*= 0.076). The genotype and allele frequencies of pri-miR-34b/c rs4938723 polymorphism in bladder cancer patients and controls are shown in ***Table 1***. The results indicated that pri-miR-34b/c rs4938723 *t*\>C polymorphism was not associated with the risk of bladder cancer in codominant (OR= 1.08, 95% CI= 0.66--1.78, *P*= 0.800; OR= 2.13. 95%CI= 0.91--5.01, *P*= 0.094, TC *vs*. TT), dominant (OR= 1.22, 95%CI= 0.76--1.95, *P*= 0.468, TC+ CC *vs.* TT), recessive (OR= 2.04, 95%CI= 0.91--4.60, *P*= 0.110, CC *vs*. TT+ TC), overdominant (OR= 0.94, 95%CI= 0.59--1.50, *P*= 0.812, TC *vs.* TT+ CC) and allelic (OR= 1.28, 95%CI= 0.90--1.82, *P*= 0.181, C *vs*. T) inheritance model tested. We also calculated adjusted OR and 95%CI for sex and age **( *Table 1*)**. The findings revealed that the variant was not associated with bladder cancer risk.

###### 

Association between pri-miR-34b/c rs4938723 *t*\>C polymorphism and risk of bladder cancer

  ------------------------------------------------------------------------------------------------
  rs4938723      Case\        Control\     OR (95%CI)          P       \*OR (95%CI)        P
                 *n* (%)      *n* (%)                                                      
  -------------- ------------ ------------ ------------------- ------- ------------------- -------
  Codominant                                                                               

  TT             54 (39.7)    64 (44.4)    1.00                \-      1.00                \-

  TC             64 (47.1)    70 (48.6)    1.08 (0.66--1.78)   0.800   1.06 (0.64--1.77)   0.813

  CC             18 (13.2)    10 (6.9)     2.13 (0.91--5.01)   0.094   2.11 (0.89--4.99)   0.089

  Dominant                                                                                 

  TT             54 (39.7)    64 (44.4)    1.00                \-      1.00                \-

  TC+ CC         82 (60.3)    80 (55.5)    1.22 (0.76--1.95)   0.468   1.19 (0.74--1.93)   0.474

  Recessive                                                                                

  TT+ TC         118 (86.8)   134 (93.1)   1.00                \-      1.00                \-

  CC             18 (13.2)    10 (6.9)     2.04 (0.91--4.60)   0.110   2.04 (0.90--4.63)   0.086

  Overdominant                                                                             

  TT+ CC         72 (52.9)    74 (51.4)    1.00                \-      1.00                \-

  TC             64 (47.1)    70 (48.6)    0.94 (0.59--1.50)   0.812   1.09 (0.67--1.75)   0.732

  Allele                                                                                   

  T              172 (41.9)   198 (68.8)   1.00                \-      \-                  \-

  C              100 (58.1)   90 (31.2)    1.28 (0.90--1.82)   0.181   \-                  \-
  ------------------------------------------------------------------------------------------------

\*adjusted for sex and age

The association between pri-miR-34b/c rs4938723 polymorphism and clinicopathological characteristics of bladder cancer patients are shown in ***Table 2***. The findings propose a significant association between age and rs4938723 variant so that the TT genotype frequencies was significantly higher in patients with ages\>60 years (48.2%) than that of patients with ages≤60 years (26.4%).

###### 

Association of rs4938723 polymorphism of Pri-miR-34b/c gene with clinicopathological characteristics of bladder cancer patients.(*n*)

  Factors                    rs4938723 *t*\>C   *P*-value           
  -------------------------- ------------------ ----------- ------- --
  Age at diagnosis (years)                                  0.039   
  ≤60                        14                 30          9       
  \>60                       40                 34          9       
  Stage                                                     0.770   
  pT2c                       0                  1           0       
  pT3b                       2                  1           1       
  LpT1                       14                 22          9       
  pT2a                       6                  6           1       
  pT2b                       2                  4           0       
  pT3a                       3                  2           2       
  HpT1                       12                 8           2       
  LpTa                       9                  14          2       
  pT4a                       1                  4           1       
  Surgical margin                                           0.647   
  Positive                   2                  3           0       
  Negative                   52                 61          18      

The genotype rs4938723 polymorphism of pri-miR-34b/c in controls and cases were in HWE (χ^2^ = 2.483, *P* = 0.115 and χ^2^ = 0.019, *P* = 0.88, respectively).

Discussion
==========

In the present study, for the first time, we inspected whether the pri-miR-34b/c rs4938723 *t*\>C polymorphism modifies the risk of bladder cancer in a sample from the Iranian population. The results showed that rs4938723 variant of pri-miR-34b/c was not associated with the risk of bladder cancer. As shown in ***Table3***, several preceding studies have investigated the association between pri-miR-34b/c rs4938723 polymorphism and cancer risk in some populations and various types of cancer with inconsistent findings. It has been shown that rs4938723 variant was not associated with the risk of breast cancer (BC)^\[[@R37]\]^ and retinoblastoma^\[[@R38]\]^. The variant has been shown to be associated with increased risk of papillary thyroid carcinoma (PTC)^\[[@R27]\]^ and nasopharyngeal carcinoma^\[[@R39]\]^. The rs4938723 variant was found to be associated with increased risk of hepatocellular carcinoma (HCC) in the Chinese^\[[@R23],[@R40]--[@R41]\]^ and Korean populations^\[[@R42]\]^.

###### 

Genotype distribution of miR-34b/c rs4938723 *t*\>C among various studies and association with risk of cancer

  Study                           Country   Cancer type                          Case/Control   Cases   Controls   Association                     
  ------------------------------- --------- ------------------------------------ -------------- ------- ---------- ------------- ----- ----- ----- ----------------
  Chen *et al.*\[^[@R27]^\]       China     Papillary thyroid carcinoma          787/1,006      271     402        111           456   451   99    Increased risk
  Li *et al.*\[^[@R39]^\]         China     Nasopharyngeal carcinoma             217/360        82      104        31            168   155   37    Increased risk
  Liu *et al.*\[^[@R40]^\]        China     Hepatocellular carcinoma             164/305        63      80         21            152   141   13    Increased risk
  Xu *et al.*\[^[@R23]^\]         China     Hepatocellular carcinoma             501/548        204     236        62            266   229   54    Increased risk
  Chen *et al.*\[^[@R41]^\]       China     Hepatocellular carcinoma             286/572        102     146        38            272   267   33    Increased risk
  Son *et al.*\[^[@R42]^\]        Korea     Hepatocellular carcinoma             157/201        69      75         13            110   74    17    Increased risk
  Pan *et al.*\[^[@R28]^\]        China     Gastric cancer                       197/289        102     76         19            121   137   31    Decreased risk
  Yang *et al.*\[^[@R43]^\]       China     Gastric cancer                       419/402        193     186        40            156   184   62    Decreased risk
  Wu *et al.*\[^[@R44]^\]         China     Gastric cancer                       897/992        405     396        92            476   430   84    No association
  Zhang *et al.*\[^[@R45]^\]      China     Esophageal squamous cell carcinoma   1,109/1,275    489     536        84            569   573   133   Decreased risk
  Zhu *et al.*\[^[@R24]^\]        China     Esophageal squamous cell carcinoma   237/274        113     99         25            122   122   30    No association
  Oh *et al.*\[^[@R46]^\]         Korea     Colorectal cancer                    545/428        272     233        40            216   171   41    No association
  Gao *et al.*\[^[@R47]^\]        China     Colorectal cancer                    347/488        175     144        28            216   210   62    Decreased risk
  Yuan *et al.*\[^[@R32]^\]       China     Cervical cancer                      328/568        117     157        36            242   258   68    Increased risk
  Zhang *et al.*\[^[@R20]^\]      China     Renal cell carcinoma                 710/760        302     324        84            352   344   64    Increased risk
  Carvalho *et al.*\[^[@R38]^\]   Brazil    Retinoblastoma                       130/105        52      64         14            45    44    16    No association
  Sanaei *et al.*\[^[@R37]^\]     Iran      Breast cancer                        263/221        125     115        23            100   106   15    No association
  Hashemi *et al.*\[^[@R48]^\]    Iran      Prostate cancer                      151/152        85      56         10            109   38    5     Increased risk
  Tong *et al.*\[^[@R49]^\]       China     Childhood ALL                        570/673        245     281        35            301   296   76    Decreases risk
  Hashemi *et al.*\[^[@R50]^\]    Iran      Childhood ALL                        110/120        77      31         2             62    52    6     Decreased risk
  Current study                   Iran      Bladder cancer                       136/144        54      64         18            64    70    10    No association

Pan *et al.* and Yang *et al.* have found that pri-miR-34b/c rs4938723 variants significantly decreased the risk of gastric cancer (GC) in Chinese population^\[[@R28],[@R43]\]^. On the other hand, the findings of Wu *et al.* did not support an association between the variant and risk of GC in Chinese population^\[[@R44]\]^. Zhang *et al.* findings revealed that rs4938723 variant significantly decreased the risk of esophageal squamous cell carcinoma (ESCC) in the Chinese population^\[[@R45]\]^. While, Zhu *et al.* has found no significant association between the variant and risk of ESCC in the Chinese population^\[[@R24]\]^.

Oh *et al.* have found no significant association between rs4938723 variant and colorectal cancer (CRC) in Korean population, while Gao *et al.* reported that this variant decrease the risk of CRC in Chinese population^\[[@R46]--[@R47]\]^. The rs4938723 variant have been shown to be associated with increased risk of cervical cancer^\[[@R32]\]^, renal cell carcinoma^\[[@R20]\]^ and prostate cancer^\[[@R48]\]^.

Tong *et al.*^\[[@R49]\]^ and Hashemi *et al.*^\[[@R50]\]^ reported that the rs4938723 variant significantly decreases the risk of childhood acute lymphoblastic leukemia (ALL).

There is no clear reason for the inconsistent findings regarding the association between pri-miR-34b/c rs4938723 variant and cancer risk. Ethnic, genetic, and/or environmental factors as well as gene-diet interaction may interact in various modes to either increase or decrease the risk of various cancers in different regions.

In summary, our findings did not support an association between rs4938723 polymorphism in the promoter region of pri-miR-34b/c and the risk of bladder cancer in a sample from the Iranian population. Further large-scale studies with diverse ethnicities are warranted to reveal the impact of rs4938723 on bladder cancer.
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